Search Results - "Yamamura, Ayuko"

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes by KADOWAKI, Takashi, NAMBA, Mitsuyoshi, YAMAMURA, Ayuko, SOWA, Hideaki, WOLKA, Anne M, BRODOWS, Robert G

“…This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally controlled despite…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by IWAMOTO, Kazuya, NASU, Risa, YAMAMURA, Ayuko, KOTHARE, Prajakti A., MACE, Kenneth, WOLKA, Anne M., LINNEBJERG, Helle

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

Improvement of glycemic control and quality-of-life by insulin lispro therapy: Assessing benefits by ITR-QOL questionnaires by Ishii, Hitoshi, Anderson, James H, Yamamura, Ayuko, Takeuchi, Masakazu, Ikeda, Ichiro

“…Abstract Objective To investigate the impact of insulin lispro on patients’ quality of life (QOL) in diabetic patients who need insulin treatment. Methods In…”
Get full text

Exenatide Exhibits Dose-Dependent Effects on Glycemic Control over 12 Weeks in Japanese Patients with Suboptimally Controlled Type 2 Diabetes by TAKASHI KADOWAKI, MITSUYOSHI NAMBA, AYUKO YAMAMURA, HIDEAKI SOWA, ANNE M.WOLKA, ROBERT G.BRODOWS

“…「Abstract」. This study assessed the dose-dependent efficacy and safety of exenatide over 12 weeks in Japanese patients with type 2 diabetes suboptimally…”
Get full text

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes by KAZUYA IWAMOTO, RISA NASU, AYUKO YAMAMURA, PRAJAKTI A.KOTHARE, KENNETH MACE, ANNE M.WOLKA, HELLE LINNEBJERG

“…This randomized, placebo-controlled, double-blind, parallel study assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once…”
Get full text

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer by Sakai, Daisuke, Chung, Hyun Cheol, Oh, Do-Youn, Park, Se Hoon, Kadowaki, Shigenori, Kim, Yeul Hong, Tsuji, Akihito, Komatsu, Yoshito, Kang, Yoon-Koo, Uenaka, Kazunori, Wijayawardana, Sameera R., Wacheck, Volker, Wang, Xuejing, Yamamura, Ayuko, Doi, Toshihiko

“…Purpose Mesenchymal–epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety,…”
Get full text

Abstract C121: A non-randomized, open-label, single-arm, phase 2 study of LY2875358 in Asian patients with MET diagnostic positive, advanced gastric cancer by Chung, Hyun Cheol, Satoh, Taroh, Oh, Do-Youn, Park, Se Hoon, Kadowaki, Shigenori, Wacheck, Volker, Yamamura, Ayuko, Uenaka, Kazunori, Wang, Xuejing Aimee, Wijayawardana, Sameera R., Doi, Toshihiko

“…Abstract Introduction: MET is expressed in gastric cancer and associated with poor clinical outcome. LY2875358 (LY) is a humanized immunoglobin G4 (IgG4)…”
Get full text

Improved glycemic control and reduced bodyweight with exenatide: A double‐blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks by Kadowaki, Takashi, Namba, Mitsuyoshi, Imaoka, Takeshi, Yamamura, Ayuko, Goto, Wakana, Boardman, Marilyn K., Sowa, Hideaki

“…Aims/Introduction:  To evaluate the efficacy and safety of the glucagon‐like peptide‐1 receptor agonist, exenatide, in Japanese patients with type 2 diabetes…”
Get full text

Long‐term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes by Inagaki, Nobuya, Ueki, Kohjiro, Yamamura, Ayuko, Saito, Hitoshi, Imaoka, Takeshi

“…Aims/Introduction:  We assessed the long‐term (52 weeks) safety and efficacy of exenatide b.i.d. in Japanese patients with type 2 diabetes and suboptimal…”
Get full text

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus by Kothare, Prajakti A., Linnebjerg, Helle, Isaka, Yoshitaka, Uenaka, Kazunori, Yamamura, Ayuko, Yeo, Kwee Poo, de la Peña, Amparo, Teng, Choo Hua, Mace, Kenneth, Fineman, Mark, Shigeta, Hirofumi, Sakata, Yukikuni, Irie, Shin

“…In this single‐blind, parallel, placebo‐controlled study, the pharmacokinetics, pharmacodynamics, tolerability, and safety of subcutaneous exenatide were…”
Get full text

Long-term safety and efficacy of exenatide twice daily in Japanese patients with suboptimally controlled type 2 diabetes: Exenatide: long-term safety and efficacy by Inagaki, Nobuya, Ueki, Kohjiro, Yamamura, Ayuko, Saito, Hitoshi, Imaoka, Takeshi

Get full text

Improved glycemic control and reduced bodyweight with exenatide: A double-blind, randomized, phase 3 study in Japanese patients with suboptimally controlled type 2 diabetes over 24 weeks: Exenatide improved glycemic control by Kadowaki, Takashi, Namba, Mitsuyoshi, Imaoka, Takeshi, Yamamura, Ayuko, Goto, Wakana, Boardman, Marilyn K., Sowa, Hideaki

Get full text